Notably, the ongoing clinical trial NCT04123379 is evaluating the combination of Nivolumab with BMS-813160—a dual CCR2/CCR5 antagonist—as a strategy to boost immune responses against non-small cell lung cancer (NSCLC), highlighting the translational relevance of targeting this axis in cancer immunotherapy [3,74]. Here, CCR2 is linked to cancer.